Alendronate Sodium Oral Solution, 70 mg/75 mL recall — Hikma Pharmaceuticals Usa Inc (Class II)
Hikma Pharmaceuticals Usa Inc is recorded by the U.S. Food and Drug Administration (FDA) as recalling Alendronate Sodium Oral Solution, 70 mg/75 mL — a Class II recall, initiated 2026-04-07 and posted to the FDA enforcement report on 2026-05-06, under recall number D-0526-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side.”. From the product description, the form is oral solution, the strengths given are 70 mg/75 mL and 75 mL and it is marked Rx only. 1 National Drug Code number is printed in the record: 0054-0282-59. Distribution is recorded as “US Nationwide” — Nationwide (US), with the recalling firm on record in OH, United States. It is the only recall number the FDA has filed under event ID 98744. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.
Regulatory snapshot
| Recall number | D-0526-2026 |
|---|---|
| FDA event ID | 98744 |
| Classification | Class II (intermediate regulatory tier) |
| Status | Ongoing |
| Recalling firm | Hikma Pharmaceuticals Usa Inc |
| Recall initiated | 2026-04-07 |
| Reported by FDA | 2026-05-06 |
| Report lag | 29 days from initiation to report |
| Distribution | US Nationwide. — Nationwide (US) |
| Firm location on record | OH, United States |
| Product description (source) | Alendronate Sodium Oral Solution, 70 mg/75 mL, 75 mL, Rx only, 4 x 75 mL Single Dose Bottles, Distr. by: Hikma Pharmaceuticals USA Inc., Berkeley Heights, NJ 07922, NDC 0054-0282-59. |
Reason reported by FDA
This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side.
23 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.
Product identifiers in this record
5 identifying values matched by exact pattern in the 30-word product description above; each is a literal substring of it.
| Product named | Alendronate Sodium Oral Solution |
|---|---|
| Form | Oral Solution |
| Strength | 70 mg/75 mL · 75 mL |
| NDC | 0054-0282-59 |
| Marketing category | Rx only |
Reported in the same month (2026-05)
48 enforcement reports carry a report date in 2026-05; these 8 are the Class II ones nearest this record.
| Recall record | Recall number | Recalling firm | FDA tier | Reported |
|---|---|---|---|---|
| Systane, 10g | D-0491-2026 | Alcon Research LLC | Class II | 2026-05-06 |
| GenTeal Tears, 10g | D-0492-2026 | Alcon Research LLC | Class II | 2026-05-06 |
| Optase Dry Eye Intense Drops (Glycerin 0.2%) | D-0499-2026 | Scope Health | Class II | 2026-05-06 |
| iVIZIA, 0.5% | D-0500-2026 | Thea Pharma, Inc. | Class II | 2026-05-06 |
| Similasan, 0.5% | D-0501-2026 | Thea Pharma, Inc. | Class II | 2026-05-06 |
| Phenylephrine Hydrochloride Injectable Solution, 40mg | D-0502-2026 | Wells Pharma OF Houston LLC | Class II | 2026-05-06 |
| fentaNYL Citrate Injectable Solution, 1000 mcg/100 mL | D-0503-2026 | Wells Pharma OF Houston LLC | Class II | 2026-05-06 |
| fentaNYL Citrate injectable Solution in 0.9% Sodium Chloride | D-0504-2026 | Wells Pharma OF Houston LLC | Class II | 2026-05-06 |
Nearest Class II recalls by date
213 of 250 indexed records share the Class II tier; the 8 nearest to 2026-05-06 by report date are listed here.
| Recall record | Recall number | Recalling firm | Strength / form | Reported |
|---|---|---|---|---|
| fentaNYL Citrate Injectable Solution, 1250 mcg/25mL | D-0505-2026 | Wells Pharma OF Houston LLC | 1250 mcg/25mL · Solution | 2026-05-06 |
| fentaNYL Citrate Injectable Solution in 0.9% Sodium Chloride | D-0506-2026 | Wells Pharma OF Houston LLC | 0.9% · Solution | 2026-05-06 |
| Ketamine Hydrochloride Injectable Solution, 50mg/ml | D-0507-2026 | Wells Pharma OF Houston LLC | 50mg/ml · Solution | 2026-05-06 |
| fentaNYL Citrate Injectable Solution in 0.9% Sodium Chloride | D-0508-2026 | Wells Pharma OF Houston LLC | 0.9% · Solution | 2026-05-06 |
| Furosemide Tablets, 80 mg | D-0486-2026 | Leading Pharma, LLC | 80 mg · Tablets | 2026-04-29 |
| FRESHKOTE LUBRICANT EYEDROPS, 10mL | D-0489-2026 | Harrow Eye LLC | 10mL | 2026-04-29 |
| Omega-3-Acid, 1 gram | D-0493-2026 | The Harvard Drug Group LLC | 1 gram · Capsules | 2026-04-29 |
| DEXTROSE INJECTION USP, 70% | D-0496-2026 | B Braun Medical Inc | 70% · Injection | 2026-04-29 |
Reading this record
Class II is the FDA's own severity tier for the recall action — 213 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual. Match a package against 0054-0282-59 at the FDA source to confirm it is covered.
Namespace context: the Class II index (213 records) and the recall hub (250 records, 118 FDA events); Hikma Pharmaceuticals Usa Inc (1 indexed records) aggregates this firm across datasets.
Coverage and limits of this record
This page reflects the openFDA enforcement report for D-0526-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.
Source & provenance
- Official source
- https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0526-2026%22
- Source dataset
- openFDA Drug Enforcement API
- Publication date
- 2026-05-06
- Ingested
- 2026-08-22
- Record hash
79ea820dbdf80018
Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.